Mantle Cell Lymphoma


Closed Funds

This fund is temporarily closed to new patients due to lack of sufficient funding. Please continue to visit our Disease Funds page often, as replenished funds reopen as quickly as possible. If you currently have a grant with HealthWell, your grant will remain active for the entire 12 month grant cycle or until you have exhausted your allocated grant amount, whichever comes first. You can continue to use your pharmacy card or submit requests for reimbursements during your designated grant cycle.

Fund Type


Maximum Award Level


Pharmacy Card Fund


Minimum Copay
Reimbursement Amount

Minimum Copay Reimbursement Amount

We encourage you to please use your HealthWell pharmacy card for any applicable charges as possible.


Minimum Premium
Reimbursement Amount

Minimum Premium Reimbursement Amount

We encourage you to please submit monthly reimbursement claims (even if your premium is paid on a bi-weekly basis).


Household Income Limit

500% of the Federal Poverty Level
(adjusted for household size and high
cost of living areas)

Fund Alerts

Sign up for email or text/call alerts to receive instant notifications.

Treatments Covered

  • Adriamycin
  • Arzerra
  • Belrapzo
  • Bendeka
  • Brukinsa
  • Calquence
  • Carboplatin
  • Cisplatin
  • Cyclophosphamide
  • Cytarabine
  • Decadron
  • Dexamethasone Sodium Phosphate
  • Dexpak 10 Day
  • Dexpak 13 Day
  • Dexpak 6 Day
  • Dextenza
  • Dexycu
  • Etopophos
  • Fusilev
  • Gazyva
  • Hidex
  • Ifex
  • Imbruvica
  • Infugem
  • Jaypirca
  • Khapsory
  • Lenalidomide
  • Leucovorin Calcium
  • Matulane
  • Maxidex
  • Medrol
  • Mesnex
  • Mitoxantronehhydrochloride
  • Navelbine
  • Otrexup
  • Oxaliplatin
  • Ozurdex
  • Rasuvo
  • Rayos
  • Revlimid
  • Riabni
  • Rituxan
  • Rituxan Hycela
  • Rituximab
  • Rituximab-pvvr
  • Ruxience
  • Solu-medrol
  • Taperdex
  • Taperdex 7 Day
  • Tecartus
  • Toposar
  • Torisel
  • Treanda
  • Trexall
  • Truxima
  • Velcade
  • Venclexta
  • Vincristine Sulfate
  • Xatmep
  • Zanubrutinib

Fund Definition

Assistance with the prescription drugs and biologics used in the treatment of Mantle Cell Lymphoma.

Grant Utilization

HealthWell estimates that patients use an average of $5,710 during their 12-month grant period for this disease area.

Consider Premium Assistance

Under this fund, HealthWell can assist with premium costs. Medicare supplemental policies can help with cost shares related to many aspects of your health care. Using a HealthWell grant to cover premiums may be a better option than treatment-specific cost shares.

Do I Qualify?

HealthWell bases eligibility on an individual’s medical, financial and insurance situation. To qualify for HealthWell’s assistance, applicants must meet the following eligibility requirements:

  • Please make sure that HealthWell currently has a fund for your diagnosis/indication and that your medication is covered under that fund by visiting our Disease Funds listing. If we do not have a fund that currently covers your diagnosis, please check back as we frequently open and reopen programs as funding becomes available. The Foundation is able to help patients receiving treatment for indications for which we currently have an open fund. We can only assist with medications that have been prescribed to treat the disease/covered diagnosis. You will be asked to provide the Foundation with the patient’s diagnosis, which must be verified by a physician, nurse practitioner, or physician assistant’s signature. The patient must receive treatment in the United States.

  • To qualify for assistance from HealthWell, you must have some form of health insurance (private insurance, Medicare, Medicaid, TriCare, etc.) that covers part of the cost of your treatment. The Foundation will refer patients without prescription insurance to other programs, such as manufacturer patient assistance programs.

  • HealthWell assists individuals with incomes up to 300-500% of the Federal Poverty Level. The Foundation also considers the number in a household and cost of living in a particular city or state. If you believe you qualify for assistance, you may begin the application process here.
  • If you are receiving treatment in the U.S. and have met the eligibility criteria as listed, you are ready to apply! Please note that you will be asked to provide a Social Security Number in order to create a grant. This information is gathered to eliminate duplicate applications and is kept secure and confidential.

About Mantle Cell Lymphoma

Mantle cell lymphoma (MCL) represents approximately 5 percent of all lymphomas. According to the American Cancer Society, MCL can be difficult to treat and tends to grow faster than indolent lymphomas and doesn’t usually respond to treatment as well as aggressive lymphomas. When a patient is diagnosed, it has usually become widespread in the lymph nodes, bone marrow, and often the spleen. MCL is more common in men than in women and most often appears in people over the age of 60.